Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 4 (1)

Trial Status

Recruiting4
Unknown2

Clinical Trials (6)

Showing 6 of 6 trials
NCT06918808Phase 2RecruitingPrimary

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

NCT05039411Phase 1RecruitingPrimary

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease

NCT06509828UnknownPrimary

Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tissue Collection

NCT06446635Not ApplicableRecruiting

Semiflex Assisted Vacuum Therapy for Perianal Abscesses/Sinuses and Fistula: a Pilot Study

NCT06051253Phase 4Recruiting

TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease

NCT05709717Unknown

Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases

Showing all 6 trials

Research Network

Activity Timeline